AUS
NZ
UK
CA
USA
IND
Highlights
- ProBiotix enters long-term exclusive supply deal with Kemin China for LPLDL® probiotic.
- The partnership focuses on expanding the reach of LPLDL® for cardiometabolic health in China.
- China’s growing $2.3 billion probiotic market presents strong growth prospects for ProBiotix.
ProBiotix Health plc (AQSE:PBX), a leader in the life sciences sector specializing in probiotics for cardiometabolic health, is excited to announce a new significant partnership with Kemin China Technology Co. Ltd (KCG). Under this agreement, KCG will exclusively market and sell ProBiotix’s proprietary probiotic strain, LPLDL®, as an ingredient for cardiometabolic health supplements in China, Hong Kong, and Macau. This long-term collaboration could lead to potential expansion into other regions, leveraging Kemin's global commercial footprint.
As part of the agreement, ProBiotix will supply LPLDL® in bulk to KCG, which will then be marketed under a co-branded arrangement. ProBiotix retains the rights to sell finished products under its own brand or as private label in China, further solidifying its presence in the fast-growing probiotic market in the region.
China presents a particularly compelling opportunity for ProBiotix, given the alarming prevalence of cardiovascular diseases. More than 330 million people in China suffer from cardiovascular conditions, with the disease being the leading cause of death, responsible for two out of every five deaths. The Chinese probiotic market itself, valued at $2.3 billion in 2024, is expected to experience significant growth, reaching $3.6 billion by 2028, driven by a 12.8% compound annual growth rate (CAGR).
Kemin, a global leader in ingredient supply, has over 60 years of expertise and operates in more than 120 countries. The company’s parent, Kemin Industries, boasts over 500 patents and annual revenues surpassing $1 billion. With Kemin’s vast network of over 15 manufacturing facilities worldwide, this collaboration aligns with their mission to enhance human health with plant-based functional ingredients in food and supplements.
Steen Andersen, CEO of ProBiotix, emphasized the importance of the partnership, stating, "With the significant prevalence of cardiovascular disease in China, this long-term collaboration with KCG is a key milestone for us. The partnership not only offers a potential growth avenue but also builds on our previous collaborations, including with Dancare for distributing finished products." He expressed excitement over the growing momentum within the business, citing the potential for sustained revenue growth and progress for shareholders.
Dr. Gan Zhilin, President of KCG, echoed Andersen's optimism, noting that the partnership aims to provide innovative and efficient cardiovascular health solutions. With ProBiotix’s cutting-edge probiotic technology and KCG’s robust market resources, this alliance promises to help address the growing global challenge of cardiovascular health.
